Pfizer's SU11248 and Novartis' PTK-787 are both cancer pills that are just becoming visible now.

FORBES: Big Pharma Could Hog Biotech's Spotlight

Novartis said that PTK-787 met one pre-planned analysis showing it delayed progression of colon cancer, but failed another.

FORBES: Two Wins For Biotech

Novartis' pill, PTK-787, hit the same molecular target as Genentech's blockbuster, and was seen as a potentially fearsome competitor.

FORBES: Two Wins For Biotech

In a note to investors, biotech analyst Matt Geller wrote that he did think PTK-787 probably came close to hitting its endpoint.

FORBES: Two Wins For Biotech

The drug giant has been hoping to repeat that success with PTK-787, a pill meant to work in the same way as Genentech's Avastin.

FORBES: Magazine Article

The drug firm may have gotten a big boost from a stalled study for PTK-787, an Avastin-like pill being developed by Novartis (nyse: NVS - news - people ).

FORBES: Chemotherapy's Juggernaut

Too much bleeding could be seen as outweighing efficacy, and newer pills could steal some of Avastin's thunder. (The drug must be given intravenously.) Data for PTK-787, a pill from Novartis (nyse: NVS - news - people ) and Germany's Schering (nyse: SHR - news - people ), which also hits VEGF, will be presented at ASCO.

FORBES: Genentech's Rite Of Spring